logo-loader
viewBiogen Inc

Biogen to produce first therapy for Alzheimer’s if FDA approves next year

Aducanumab aims at reducing the clinical decline of the disease rather than the underlying cause

Biogen Inc - Biogen to produce first therapy for Alzheimer’s if FDA approves next year

Biogen Inc’s (NASDAQ:BIIB) potential treatment for Alzheimer’s would become the first therapy of its kind if approved by the US Food and Drug Administration (FDA).

It aims at reducing the clinical decline of the disease, which accounts for 60-80% of dementia cases, rather than the underlying cause.

It would stop the deterioration of cognitive abilities so patients can perform daily activities, including conducting personal finances, performing household chores and independently travelling out of the home. 

The FDA, which granted priority review to aducanumab, is expected to take a decision by next March.

The pharma company stopped the final phase of clinical trials last year after early data showed it would not be beneficial for patients in the early stages of the disease.

But Biogen applied to the FDA after retrieving a wider pool of data, while it is also planning a new study involving the same participants of the previous trial.

“We believe that aducanumab marks the beginning of a new era of potential treatments for Alzheimer’s disease that will inspire even more discovery and innovation to bring hope to those affected by this devastating disease,” said chief executive Michel Vounatsos.

Shares added 1% to US$309.34 in premarket trading.

Quick facts: Biogen Inc

Price: 274.48 USD

NASDAQ:BIIB
Market: NASDAQ
Market Cap: $43.45 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: FTSE fragile Friday despite UK shoppers continuing to splurge...

Good morning, it’s a fragile Friday for the FTSE despite signs of some retail therapy as British retail sales continued to increase for the fourth consecutive month, boosted by spending on household goods and DIY, according to the ONS.  J Sainsbury PLC (LON:SBRY) is up after a...

2 days, 3 hours ago

2 min read